Krystal Biotech expands to oncology; FDA accepts IND for KB707 for solid tumors

Krystal Biotech, Inc.

FDA accepted IND for KB707, a modified HSV-1 vector delivering IL-12 and IL-2 for solid tumors.
Two formulations: intratumoral injection for accessible tumors and inhaled (nebulized) for lung delivery.
Phase 1 Opal 1 study to start 2H 2023; amendment for inhaled formulation expected in 2H 2023.
Preclinical data showed antitumor responses in checkpoint-inhibitor-refractory mouse models.
Investor conference call on July 27, 2023 at 8:00 AM ET to discuss KB707 program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.